Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482247 · ClinicalTrials.gov registry record · Phase 2
L-Arginine, Vascular Response and Mechanisms
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01482247 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 25 participants.
The verdict
NCT01482247, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of the study is to employ the supplement L-arginine to test the hypothesis that activation of blood flow to the brain during cognitive tasks is regulated by nitric oxide in older subjects with diabetes mellitus and/or hypertension (high blood pressure).
Interventions
- DIETARY_SUPPLEMENT Placebo Supplement
- DIETARY_SUPPLEMENT L-Arginine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01482247
The ClinicalTrials.gov registry entry for NCT01482247 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Supplement is the first listed.
NCT01482247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01482247 about?
NCT01482247 is a clinical study titled "L-Arginine, Vascular Response and Mechanisms". The purpose of the study is to employ the supplement L-arginine to test the hypothesis that activation of blood flow to the brain during cognitive tasks is regulated by nitric oxide in older subjects with diabetes mellitus and/or hypertension (high blood pressure).
What is the current status of trial NCT01482247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2012-04. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01482247?
The interventions under investigation include: Placebo Supplement (DIETARY_SUPPLEMENT), L-Arginine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01482247?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.